文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

阿奇霉素联合标准治疗与单用标准治疗重型COVID-19住院患者的随机临床试验(COALITION II)

Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.
PubMed 文献 · Lancet · 2020-09-05

该研究在巴西57个中心开展开放标签随机临床试验,纳入447例疑似或确诊重型COVID-19住院患者,随机接受阿奇霉素联合标准治疗(含羟氯喹)或单用标准治疗。

要点

  • 在重型COVID-19住院患者中,阿奇霉素联合含羟氯喹的标准治疗未改善第15天临床状态。
  • 两组不良事件率无显著差异,包括室性心律失常、心脏骤停、急性肾衰竭和QT间期延长。
  • 研究结果不支持在重型COVID-19患者中常规使用阿奇霉素联合羟氯喹。

核心结论

  • 在重型COVID-19住院患者中,标准治疗基础上加用阿奇霉素未改善临床结局。
  • 研究结果不支持常规使用阿奇霉素联合羟氯喹治疗重型COVID-19患者。

研究设计与样本

  • 开放标签随机临床试验,在巴西57个中心开展,纳入447例疑似或确诊重型COVID-19住院患者。
  • 患者按1:1随机分配至阿奇霉素500mg每日一次(口服、鼻胃管或静脉给药)共10天联合标准治疗组,或单用标准治疗(不含大环内酯类)组。
  • 所有患者均接受羟氯喹400mg每日两次共10天作为巴西重型COVID-19标准治疗的一部分。
  • 主要终点为随机后第15天采用六分类量表评估的临床状态,由对治疗分配设盲的独立裁定委员会评估。
  • 主要终点在改良意向治疗人群中分析,即随机前经分子或血清学检测确诊SARS-CoV-2感染的397例患者(阿奇霉素组214例,对照组183例)。

主要发现

  • 不良事件率(包括临床相关室性心律失常、心脏骤停复苏、急性肾衰竭和校正QT间期延长)两组间无显著差异。

关键数值与推荐

  • 纳入标准:疑似或确诊COVID-19住院患者,且至少满足一项额外严重性标准:氧疗流量>4L/min、使用高流量鼻导管、使用无创机械通气或使用有创机械通气。
  • 阿奇霉素用法:500mg每日一次,口服、鼻胃管或静脉给药,共10天。
  • 羟氯喹用法:400mg每日两次,共10天。

临床怎么用

  • 对于重型COVID-19住院患者,不建议在含羟氯喹的标准治疗基础上常规加用阿奇霉素。
  • 临床决策应基于当前证据和指南,避免使用未证实获益的联合方案。

局限性

  • 开放标签设计可能引入偏倚。
  • 所有患者均接受羟氯喹,可能影响阿奇霉素效应的独立评估。
  • 研究在巴西特定医疗环境下进行,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy and safety of azithromycin in the treatment of COVID-19 remain uncertain. We assessed whether adding azithromycin to standard of care, which included hydroxychloroquine, would improve clinical outcomes of patients admitted to the hospital with severe COVID-19. METHODS: We did an open-label, randomised clinical trial at 57 centres in Brazil. We enrolled patients admitted to hospital with suspected or confirmed COVID-19 and at least one additional severity criteria as follows: use of oxygen supplementation of more than 4 L/min flow; use of high-flow nasal cannula; use of non-invasive mechanical ventilation; or use of invasive mechanical ventilation. Patients were randomly assigned (1:1) to azithromycin (500 mg via oral, nasogastric, or intravenous administration once daily for 10 days) plus standard of care or to standard of care without macrolides. All patients received hydroxychloroquine (400 mg twice daily for 10 days) because that was part of standard of care treatment in Brazil for patients with severe COVID-19. The primary outcome, assessed by an independent adjudication committee masked to treatment allocation, was clinical status at day 15 after randomisation, assessed by a six-point ordinal scale, with levels ranging from 1 to 6 and higher scores indicating a worse condition (with odds ratio [OR] greater than 1·00 favouring the control group). The primary outcome was assessed in all patients in the intention-to-treat (ITT) population who had severe acute respiratory syndrome coronavirus 2 infection confirmed by molecular or serological testing before randomisation (ie, modified ITT [mITT] population). Safety was assessed in all patients according to which treatment they received, regardless of original group assignment. This trial was registered at ClinicalTrials.gov, NCT04321278. FINDINGS: 447 patients were enrolled from March 28 to May 19, 2020. COVID-19 was confirmed in 397 patients who constituted the mITT population, of whom 214 were assigned to the azithromycin group and 183 to the control group. In the mITT population, the primary endpoint was not significantly different between the azithromycin and control groups (OR 1·36 [95% CI 0·94-1·97], p=0·11). Rates of adverse events, including clinically relevant ventricular arrhythmias, resuscitated cardiac arrest, acute kidney failure, and corrected QT interval prolongation, were not significantly different between groups. INTERPRETATION: In patients with severe COVID-19, adding azithromycin to standard of care treatment (which included hydroxychloroquine) did not improve clinical outcomes. Our findings do not support the routine use of azithromycin in combination with hydroxychloroquine in patients with severe COVID-19. FUNDING: COALITION COVID-19 Brazil and EMS.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Furtado RHM, Berwanger O, Fonseca HA, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020. PMID: 32896292. doi:10.1016/S0140-6736(20)31862-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。